Stock listing
Frankfurt:0JV0 iBio, Inc. Aktie
German listing (Frankfurt) of iBio, Inc. · home listing NASDAQ:IBIO
Follow iBio, Inc. into a list and get an email when it puts out news.
Share price · FWB:0JV0
€0.714 EUR 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- €0.677 – €0.714 EURNov 20, 2026
- Market cap
- €45.92M EURAt the close on Nov 20, 2026 · price × 64.31M shares outstanding
- 52-week range
- €0.591 – €2.621 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €449 EURMedian day 0 shares · 47 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IBIO · Home | $0.80 USD | -0.048 (-5.7%) | 3,363,632 | $0.796 | $0.827 | $0.763 | $0.848 | Close on Nov 20, 2026 |
| Frankfurt:0JV0 | €0.714 EUR | 0.000 (0.0%) | — | €0.677 | €0.714 | €0.677 | €0.714 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:0JV0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.662 | +0.039 | +6.3% | €0.602 | €0.662 | €0.598 | 0 | |
| €0.623 | -0.097 | -13.5% | €0.658 | €0.658 | €0.614 | 0 | |
| €0.720 | +0.027 | +3.9% | €0.680 | €0.722 | €0.678 | 4 | |
| €0.693 | +0.017 | +2.5% | €0.665 | €0.696 | €0.663 | 0 | |
| €0.676 | 0.000 | 0.0% | €0.682 | €0.682 | €0.675 | 0 | |
| €0.676 | -0.018 | -2.6% | €0.676 | €0.676 | €0.676 | 0 | |
| €0.694 | +0.045 | +6.9% | €0.678 | €0.703 | €0.675 | 15,968 | |
| €0.649 | -0.009 | -1.4% | €0.649 | €0.649 | €0.649 | 0 | |
| €0.658 | +0.044 | +7.2% | €0.593 | €0.658 | €0.591 | 0 | |
| €0.614 | -0.044 | -6.7% | €0.601 | €0.614 | €0.591 | 6 | |
| €0.658 | -0.036 | -5.2% | €0.658 | €0.658 | €0.658 | 9,490 | |
| €0.694 | -0.032 | -4.4% | €0.694 | €0.694 | €0.694 | 0 | |
| €0.726 | +0.097 | +15.4% | €0.679 | €0.738 | €0.679 | 0 | |
| €0.629 | -0.027 | -4.1% | €0.629 | €0.629 | €0.629 | 0 | |
| €0.656 | +0.007 | +1.1% | €0.642 | €0.659 | €0.641 | 0 | |
| €0.649 | -0.049 | -7.0% | €0.649 | €0.649 | €0.649 | 0 | |
| €0.698 | +0.050 | +7.7% | €0.646 | €0.698 | €0.642 | 0 | |
| €0.648 | -0.100 | -13.4% | €0.648 | €0.648 | €0.648 | 0 | |
| €0.748 | +0.018 | +2.5% | €0.753 | €0.755 | €0.741 | 0 | |
| €0.730 | -0.033 | -4.3% | €0.730 | €0.730 | €0.730 | 0 | |
| €0.763 | -0.084 | -9.9% | €0.763 | €0.763 | €0.763 | 2,210 | |
| €0.847 | -0.018 | -2.1% | €0.847 | €0.847 | €0.847 | 4,000 | |
| €0.865 | -0.060 | -6.5% | €0.881 | €0.885 | €0.864 | 0 | |
| €0.925 | -0.025 | -2.6% | €0.944 | €0.951 | €0.922 | 0 | |
| €0.950 | -0.024 | -2.5% | €0.950 | €0.950 | €0.950 | 0 | |
| €0.974 | -0.020 | -2.0% | €0.943 | €0.983 | €0.940 | 2 | |
| €0.994 | +0.015 | +1.5% | €0.995 | €0.995 | €0.993 | 0 | |
| €0.979 | +0.006 | +0.6% | €0.979 | €0.979 | €0.979 | 0 | |
| €0.973 | -0.018 | -1.8% | €0.973 | €0.973 | €0.973 | 0 | |
| €0.991 | -0.038 | -3.7% | €0.991 | €0.991 | €0.991 | 0 | |
| €1.029 | -0.003 | -0.3% | €1.012 | €1.030 | €1.004 | 2,224 | |
| €1.032 | -0.069 | -6.3% | €1.033 | €1.035 | €1.032 | 0 | |
| €1.101 | -0.037 | -3.3% | €1.122 | €1.125 | €1.092 | 0 | |
| €1.138 | +0.056 | +5.2% | €1.058 | €1.139 | €1.042 | 0 | |
| €1.082 | -0.006 | -0.6% | €1.073 | €1.091 | €1.073 | 0 | |
| €1.088 | +0.113 | +11.6% | €1.051 | €1.094 | €1.049 | 0 | |
| €0.975 | -0.008 | -0.8% | €0.975 | €0.975 | €0.975 | 0 | |
| €0.983 | -0.026 | -2.6% | €0.983 | €0.983 | €0.983 | 0 | |
| €1.009 | -0.026 | -2.5% | €0.991 | €1.013 | €0.990 | 0 | |
| €1.035 | +0.025 | +2.5% | €1.001 | €1.038 | €1.001 | 0 | |
| €1.010 | -0.018 | -1.8% | €1.010 | €1.010 | €1.010 | 0 | |
| €1.028 | -0.049 | -4.5% | €1.028 | €1.028 | €1.028 | 0 | |
| €1.077 | -0.015 | -1.4% | €1.070 | €1.078 | €1.070 | 0 | |
| €1.092 | +0.020 | +1.9% | €1.075 | €1.110 | €1.068 | 0 | |
| €1.072 | -0.095 | -8.1% | €1.072 | €1.072 | €1.072 | 0 | |
| €1.167 | +0.094 | +8.8% | €1.075 | €1.178 | €1.071 | 500 | |
| €1.073 | +0.031 | +3.0% | €1.073 | €1.073 | €1.073 | 0 | |
| €1.042 | +0.003 | +0.3% | €1.042 | €1.042 | €1.042 | 0 | |
| €1.039 | -0.080 | -7.1% | €1.039 | €1.039 | €1.039 | 0 | |
| €1.119 | -0.044 | -3.8% | €1.119 | €1.119 | €1.119 | 0 | |
| €1.163 | -0.009 | -0.8% | €1.163 | €1.163 | €1.163 | 264 | |
| €1.172 | -0.033 | -2.7% | €1.172 | €1.172 | €1.172 | 0 | |
| €1.205 | +0.040 | +3.4% | €1.205 | €1.205 | €1.205 | 0 | |
| €1.165 | -0.014 | -1.2% | €1.165 | €1.165 | €1.165 | 0 | |
| €1.179 | -0.028 | -2.3% | €1.179 | €1.179 | €1.179 | 0 | |
| €1.207 | -0.019 | -1.5% | €1.207 | €1.207 | €1.207 | 0 | |
| €1.226 | +0.031 | +2.6% | €1.226 | €1.226 | €1.226 | 0 |
Splits
2 splits since 2018 · FWB:0JV0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- Frankfurt:0JV0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
iBio to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed €0.693 (+2.5%) on Nov 3, 2026
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
Oct 13, 2026
Closed €0.748 (+2.5%) on Oct 13, 2026
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
Sep 16, 2026
Closed €0.983 (-2.6%) on Sep 16, 2026
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
Sep 1, 2026
Closed €1.04 (+0.3%) on Sep 2, 2026
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Aug 28, 2026
Closed €1.16 (-0.8%) on Aug 28, 2026
IntraBio’s Pivotal Phase III Trial in CACNA1A-Related Disorders Is Enrolling and Is Expected to Be Over-Enrolled and Complete Recruitment in October
Aug 19, 2026
Closed €1.20 (-0.3%) on Aug 19, 2026
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
Aug 4, 2026
Closed €1.19 (+1.1%) on Aug 4, 2026
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia
Jun 5, 2026
Closed €1.52 (-5.7%) on Jun 8, 2026
iBio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 118 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 21 decks · latest November 2026
Where iBio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IBIO · Home listing | NASDAQ | United States | USD |
| Tradegate:0JV0 | Tradegate | Germany | EUR |
| gettex:0JV0 | gettex | Germany | EUR |
| BOATS:IBIO | BOATS | United States | USD |
| Munich:0JV0 | Munich | Germany | EUR |
| Frankfurt:0JV0 · This page | Frankfurt | Germany | EUR |
| Stuttgart:0JV0 | Stuttgart | Germany | EUR |
Valuation
EV/sales −21.5× against a median of 124×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$23.13M USD
- P/E
- Loss
- EV/sales
- −21.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- 126.9%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.07M | US$13.13M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Acrivon Therapeutics, Inc. · NASDAQ:ACRV | US$49.35M | −US$26.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.09 |
| Median of the others | US$51.67M | US$11.43M | 33.0× | 124× | 0.9× | −393.3% | 0.0× | 0.66 |
Forecasts
8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.69 USD · Analysts' mean
- EPS, year to Jun 2027
- -0.37 · 9 analysts
- Revenue, year to Jun 2027
- 25K · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Brenner | Chief Executive Officer and Chief Scientific Officer |
| Felipe Duran | Chief Financial Officer |
| Marc Banjak | Chief Legal Officer |
| Endocrinologist Molly Carr | Chief Medical Officer |
| Molly Carr | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Chip Clark | Chairman of the Board |
| Alexandra Kropotova | Director |
| António Parada | Director |
| David Arkowitz | Director |
| Elizabeth Stoner | Director |
| Gary Sender | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 10, 2026 · After close | +5.7% |
| Q4 2026 | Aug 28, 2026 · Before open | −2.9% |
| Q3 2026 | May 13, 2026 | −3.1% |
| Q2 2026 | Feb 10, 2026 · After close | −2.6% |
| Q1 2026 | Nov 12, 2025 | −7.3% |
| Q4 2025 | Sep 5, 2025 · Before open | +3.7% |
| Q3 2025 | May 2, 2025 · Before open | −1.9% |
| Q2 2025 | Feb 10, 2025 · After close | −7.3% |
| Q1 2025 | Nov 12, 2024 · After close | −9.0% |
| Q4 2024 | Sep 25, 2024 · After close | +7.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 13, 2024 · After close | +3.3% |
| Q2 2024 | Feb 9, 2024 · After close | +2.5% |
| Q1 2024 | Nov 13, 2023 · After close | −3.5% |
| Q4 2023 | Sep 27, 2023 · After close | 0.0% |
| Q3 2023 | May 15, 2023 · Before open | −6.9% |
| Q2 2023 | Feb 14, 2023 · After close | −3.4% |
| Q1 2023 | Oct 11, 2022 · After close | −1.6% |
| Q4 2022 | Sep 27, 2022 · After close | −34.4% |
| Q3 2022 | May 12, 2022 · After close | −7.4% |
| Q2 2022 | Feb 14, 2022 · After close | −2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 29 slides | September 2026 |
| Investor Presentation (March 2026) | Investor deck | 39 slides | Mar 9, 2026 |
| Investor Presentation (August 2025) | Investor deck | 34 slides | Aug 18, 2025 |
| Investor Presentation (June 2025) | Investor deck | 45 slides | Jun 24, 2025 |
| Investor Presentation (April 2025) | Investor deck | 87 slides | Apr 8, 2025 |
| Investor Presentation (January 2025) | Investor deck | 81 slides | Jan 10, 2025 |
| Investor Presentation (October 2024) | Investor deck | 72 slides | Oct 23, 2024 |
| Investor Presentation (June 2024) | Investor deck | 67 slides | Jun 3, 2024 |
| Investor Presentation (January 2024) | Investor deck | 66 slides | Jan 8, 2024 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 53 slides | Oct 2, 2023 |
| Investor Presentation (July 2023) | Investor deck | 47 slides | Jul 10, 2023 |
| Investor Presentation (April 2023) | Investor deck | 46 slides | Apr 24, 2023 |
| Investor Presentation (November 2022) | Investor deck | 33 slides | Nov 3, 2022 |
| Investor Presentation (October 2022) | Investor deck | 23 slides | Oct 3, 2022 |
| Investor Presentation (May 2022) | Investor deck | 29 slides | May 16, 2022 |
| Investor Presentation (March 2022) | Investor deck | 30 slides | Mar 18, 2022 |
| Investor Presentation (August 2021) | Investor deck | 32 slides | Aug 30, 2021 |
| IPO Roadshow (October 2019) | IPO roadshow | 24 slides | Oct 11, 2019 |
| IPO Roadshow (June 2018) | IPO roadshow | 24 slides | Jun 13, 2018 |
| Noble Financial Sixth Annual Equity Conference ONTRACK 2010 | Conference | 25 slides | Jun 4, 2010 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants in lieu thereof) Announced: about US$26M · US$2.35 a share · Leerink Partners +2 Dealers: Leerink Partners (lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead) Buyers: Frazier Life Sciences Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610, IBIO-600 and bispecifics, other pipeline assets, working capital and general corporate purposes | Jan 9, 2026 |
| Public offering of pre-funded warrants and accompanying Series G warrants Closed: US$50M raised · US$0.699 a share · ½ warrant at US$0.7 · Leerink Partners +3 Dealers: Leerink Partners (lead), LifeSci Capital, Oppenheimer & Co., Brookline Capital Markets Buyers: Balyasny Asset Management; Cormorant Asset Management; Adage Capital Partners LP; Ally Bridge Group; Marshall Wace; Coastlands Capital; SilverArc Capital Management; Vestal Point Capital; Ausangate Capital Use of proceeds: Advance preclinical cardiometabolic programs incl. IBIO-610 and IBIO-600, other pipeline assets, working capital and general corporate purposes | Aug 25, 2025 |
| Warrant exercise of shares of common stock upon exercise of existing warrants Announced: about US$6.2M · US$1.11 a share · Warrants at US$0.86 for 60 months · Chardan Dealers: Chardan Use of proceeds: Working capital and other general corporate purposes | Apr 29, 2025 |
| Private placement of private placement offering Closed: US$650,000 raised Insiders: Private placement with members of its Board of Directors and Officers | Jan 13, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100.0K | 400.0K | 225.0K | 0 | 1.88M | 2.37M | 1.64M | 2.02M | 444.0K | 394.0K |
| Cost of revenue | 1.03M | 1.25M | 1.11M | 216.0K | 1.46M | 703.0K | 13.0M | 13.0M | ||
| Gross profit | 100.0K | 400.0K | 225.0K | 50.0K | 2.17M | 909.0K | 935.0K | 2.02M | 444.0K | 394.0K |
| Research and development | 19.6M | 8.31M | 5.18M | 10.3M | 9.83M | 9.99M | 3.57M | 5.47M | 3.99M | 4.12M |
| Selling, general and administrative | 10.6M | 10.7M | 11.7M | 19.0M | 21.8M | 21.7M | 11.4M | 12.3M | 10.7M | 10.6M |
| Operating income | -35.1M | -18.6M | -16.6M | -29.3M | -29.7M | -31.1M | -14.0M | -15.8M | -14.2M | -14.3M |
| Depreciation and amortization | 558.0K | 484.0K | 638.0K | 674.0K | 2.27M | 472.0K | 282.0K | 179.0K | 1.37M | 1.33M |
| EBITDA | -34.6M | -18.1M | -16.0M | -28.7M | -27.4M | -30.6M | -13.7M | -15.6M | -12.9M | -12.9M |
| Interest expense | 53.0K | 212.0K | 172.0K | 83.0K | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M |
| Income before tax | -33.0M | -18.4M | -15.4M | -29.3M | -29.5M | -23.2M | -16.4M | -17.6M | -16.1M | -14.5M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -33.0M | -18.4M | -24.9M | -65.0M | -50.3M | -23.2M | -16.4M | -17.6M | -16.1M | -14.5M |
| Earnings per share, basic | -0.32 | -1.75 | -6.50 | -106.19 | -5.78 | -3.00 | -0.61 | -0.94 | -1.54 | -1.64 |
| Earnings per share, diluted | -0.32 | -1.75 | -6.50 | -106.19 | -5.78 | -3.00 | -0.61 | -0.94 | -1.54 | -1.64 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 56.4M | 8.58M | 14.2M | 4.30M | 22.7M | 77.4M | 55.1M | 4.42M | 4.42M | 15.9M |
| Short-term investments | 31.6M | 0 | 0 | 0 | 10.8M | 19.6M | 0 | 0 | 0 | |
| Receivables | 1.10M | 0 | 0 | 0 | 1.00M | 426.0K | 75.0K | 97.0K | 75.0K | 175.0K |
| Inventory | 0 | 0 | 3.90M | 27.0K | 798.0K | 1 | 0 | 26.0K | ||
| Current assets | 92.2M | 9.72M | 15.7M | 26.3M | 45.1M | 104.6M | 61.7M | 4.81M | 16.3M | 8.57M |
| Property, plant and equipment | 3.09M | 3.16M | 3.63M | 4.22M | 1.37M | 8.63M | 3.66M | 24.4M | 25.2M | 25.6M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 99.1M | 23.2M | 28.7M | 41.2M | 99.4M | 147.0M | 94.2M | 30.6M | 43.1M | 36.0M |
| Accounts payable | 4.42M | 2.19M | 358.0K | 1.85M | 4.26M | 2.25M | 1.76M | 1.00M | 790.0K | 749.0K |
| Current liabilities | 11.7M | 6.11M | 3.84M | 22.1M | 30.4M | 6.64M | 5.24M | 3.46M | 2.04M | 2.01M |
| Long-term debt | 766.0K | 339.0K | 24.9M | 25.1M | ||||||
| Total debt | 2.20M | 3.51M | 4.46M | 17.1M | 25.8M | 32.7M | 32.9M | 24.9M | 25.1M | 25.3M |
| Total liabilities | 13.4M | 8.30M | 7.41M | 25.8M | 35.9M | 38.4M | 37.6M | 28.1M | 26.9M | 27.1M |
| Shareholders' equity | 85.7M | 14.9M | 21.3M | 15.4M | 63.5M | 108.6M | 56.6M | 2.46M | 16.2M | 8.91M |
| Shares outstanding | 55.7M | 19.3M | 8.62M | 1.02M | 8.73M | 8.71M | 140.1M | 20.2M | 16.0M | 8.91M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.2M | -15.3M | -18.6M | -30.4M | -37.5M | -30.1M | -13.3M | -14.0M | -13.5M | -13.2M |
| Capital spending | -578.0K | -16.0K | -210.0K | -5.74M | -7.33M | -4.92M | -1.08M | -920.0K | -934.0K | -1.32M |
| Free cash flow | -23.8M | -15.3M | -18.8M | -36.2M | -44.8M | -35.0M | -14.4M | -14.9M | -14.4M | -14.5M |
| Cash from investing | -32.0M | 742.0K | 906.0K | 7.01M | -5.13M | -26.5M | -1.15M | -990.0K | -1.08M | -1.59M |
| Cash from financing | 103.0M | 8.93M | 24.5M | 2.30M | -6.13M | 78.8M | 65.2M | 3.45M | 22.4M | -170.0K |
| Dividends paid | -500.0K | -21.6M | 0 | 0 | ||||||
| Share buybacks | 0 | -7.00K | -39.0K | 0 | -40.8M | -159.0K | -125.0K | 0 | ||
| Change in cash | 47.8M | -5.63M | 6.85M | -21.1M | -48.7M | 22.3M | 50.7M | -11.5M | 7.85M | -14.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 8-K · Current report | Oct 19, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Sep 4, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 4, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Aug 28, 2026 | Annual report | SEC |
| 8-K · Current report | Aug 28, 2026 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Aug 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 8-K · Current report | May 8, 2026 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Apr 17, 2026 | Current report | SEC |
| 8-K · Current report | Apr 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 9, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 4, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 4, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 27, 2026 | Material contract | SEC |
| S-3 · Registration statement | Feb 27, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 10, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 9, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 5, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 22, 2026 | Big-stake notice | SEC |
| D | Jan 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 17, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Oct 6, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 6, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Sep 5, 2025 | Annual report | SEC |
| 8-K · Current report | Sep 5, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 21, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 21, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2025 | Results | SEC |
| 424B5 · Prospectus | Aug 18, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| S-3 · Registration statement | Jun 13, 2025 | Offer document | SEC |
| D | May 7, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 2, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2025 | Results | SEC |
| 424B5 · Prospectus | Apr 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Apr 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Apr 30, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 22, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 25 | Mar 3, 2025 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Mar 3, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Mar 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 11, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 11, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 10, 2025 | Results | SEC |
| CORRESP · Letter to the SEC | Feb 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 31, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jan 31, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 2, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Oct 23, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Oct 10, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 10, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Sep 24, 2024 | Annual report | SEC |
| 10-K · Annual report | Sep 20, 2024 | Annual report | SEC |
| 8-K · Current report | Sep 20, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 7, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Aug 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 26, 2024 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jul 25, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 18, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2024 | Management or board change | SEC |
| 8-K · Current report | Jul 3, 2024 | Material contract | SEC |
| S-3 · Registration statement | Jul 3, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 5, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 8-K · Current report | May 20, 2024 | Material contract | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 26, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 16, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 8, 2024 | Big-stake notice | SEC |
This page holds 200 of 914 filings. Open Filings
Cap table
Built by 6ix from iBio, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 64,307,256
- Fully diluted
- 64,307,256
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 64,307,256 | Sep 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.70 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 64,307,256 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Arkowitz Other companies: Kineta Inc. (Director · Since at least Mar 6, 2019); Seres Therapeutics, Inc. (Chief Financial Officer · Jun 1, 2021 – Feb 14, 2024 · Past); Flexion Therapeutics Inc (Chief Financial Officer · May 7, 2018 – May 10, 2021 · Past); Spring Bank Pharmaceuticals Inc (Director · May 5, 2016 – Jun 24, 2020 · Past); AMAG Pharmaceuticals Inc (EVP, CFO and CBO · Apr 5, 2007 – May 31, 2011 · Past); Idenix Pharmaceuticals Inc (Chief Financial Officer · Mar 7, 2006 – Mar 6, 2007 · Past) | Director · Since at least Nov 21, 2024 |
| Douglas Beck Other companies: SHF Holdings, Inc. (PAO SVP of Finance Controller · Since at least Sep 24, 2025); ShiftPixy Inc (Chief Financial Officer · Jan 15, 2023 – Jan 15, 2023 · Past); Beyond Air, Inc. (Chief Financial Officer · Nov 1, 2018 – Jun 16, 2021 · Past); Relmada Therapeutics, Inc. (Chief Financial Officer · Jan 6, 2015 – Feb 23, 2015 · Past); Lev Pharmaceuticals Inc (Chief Financial Officer · Jun 7, 2006 – Jun 7, 2006 · Past) | Chief Financial Officer · May 3, 2011 – May 3, 2011 · Past |
| Gary Sender Other companies: Apnimed, Inc. (Director · Since at least Jul 30, 2026); Harmony Biosciences Holdings, Inc. (Director · Since at least Aug 18, 2020); Schrodinger, Inc. (Board Member · Since at least Feb 5, 2020); Nabriva Therapeutics AG (Chief Financial Officer · Dec 30, 2016 – Feb 28, 2021 · Past); Synergy Pharmaceuticals Inc (EVP and CFO · Nov 16, 2015 – Nov 16, 2015 · Past) | Director · Since at least Oct 14, 2020 |
| Evert Schimmelpennink Other companies: Contineum Therapeutics, Inc. (President, LENZ Therapeutics · Since at least Apr 4, 2024); LENZ Therapeutics, Inc. (President, Chief Executive Officer, Secretary and Director · Since at least Mar 21, 2024); Pfenex Inc (See Remarks, Director · Oct 1, 2020 – Oct 1, 2020 · Past) | Director · Since at least Jun 7, 2021 |
| Elizabeth Stoner Other companies: Radius Health, Inc. (Director · Dec 17, 2014 – Dec 17, 2014 · Past); Momenta Pharmaceuticals Inc (Director · Jun 11, 2013 – Oct 1, 2020 · Past) | Director · Since at least May 7, 2026 |
| Alexandra Kropotova Other companies: SAB Biotherapeutics, Inc. (CHIEF MEDICAL OFFICER · Since at least Mar 27, 2025) | Director · Since at least Nov 20, 2025 |
| Chip Clark Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025) | Chairman of the Board · Since at least Nov 5, 2026 |
| Dina Masi Other companies: Integrated BioPharma, Inc. (Chief Financial Officer · Since at least Jun 30, 2008) | Interim CFO · Aug 12, 2008 – Aug 12, 2008 · Past |
| John Delta Other companies: Motorsport Games Inc. (Director · Since at least Oct 4, 2022) | Principal Accounting Officer · Oct 1, 2020 – Oct 1, 2020 · Past |
| Jules A Musing Other companies: TherapeuticsMD, Inc. (Director · May 16, 2013 – Sep 29, 2022 · Past) | Director · Feb 1, 2012 – Jul 24, 2012 · Past |
All 29 people
| Person | Seat |
|---|---|
| Martin Brenner Other companies: Pfenex Inc (Chief Scientific Officer · Mar 18, 2019 – Oct 1, 2020 · Past) | Chief Executive Officer and Chief Scientific Officer · Since at least Jan 18, 2021 |
| William D Clark Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025) | Director · Since at least Nov 21, 2024 |
| António Parada | Director · Since at least Nov 21, 2024 |
| Arthur Y Elliott | Director · Oct 29, 2010 – Apr 1, 2019 · Past |
| Endocrinologist Molly Carr | Chief Medical Officer · Since at least Aug 4, 2026 |
| Felipe Duran | Chief Financial Officer · Since at least Feb 13, 2023 |
| Geoffrey C Schild | Chief Scientific Officer · Aug 12, 2008 – Aug 12, 2008 · Past |
| Glenn Chang | Director · Feb 20, 2019 – Dec 9, 2021 · Past |
| Hill James T General | Director · Dec 9, 2021 – Dec 9, 2021 · Past |
| James P Mullaney | Chief Financial Officer · Mar 1, 2017 – May 27, 2020 · Past |
| Jennifer L Kmiec | VP, Bus. Dev. and Marketing · Aug 12, 2008 – Aug 12, 2008 · Past |
| John D McKey Jr | Director · Aug 12, 2008 – Dec 9, 2021 · Past |
| Marc Banjak | Chief Legal Officer · Since at least Aug 14, 2024 |
| Molly Carr | Chief Medical Officer · Since at least Jul 31, 2026 |
| Philip K Russell | Director · Feb 20, 2019 – Apr 1, 2019 · Past |
| Robert Kay | Director · Feb 13, 2009 – Jun 12, 2020 · Past |
| Robert L Erwin | President · Aug 12, 2008 – Jun 4, 2020 · Past |
| Ryan E Terence | Chief Scientific Officer · Feb 20, 2019 – Feb 20, 2019 · Past |
| Seymour Flug | Director · Dec 18, 2012 – Apr 1, 2019 · Past |
Log in to ask 6ix AI your own questions about iBio, Inc.